Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Northwest Biotherapeutics NWBT

No earlier versions found for this Subject.

Return to Northwest Biotherapeutics NWBT

Northwest Biotherapeutics, Inc. is a biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company combines its expertise in dendritic cell biology, monoclonal antibodies, immunology and antigen discovery with its proprietary technologies to develop cancer therapies. These therapies are derived from Northwest's two product development programs, DCVax and HuRx. DcVax is a dedritic cell-based cancer immunotherapy platform. The Company is developing four DCVax product candidates that include DCVax-Prostate, DCVax-Brain, DCVax-Lung and the fourth is in pre-clinical development. HuRx is the Company's fully human monoclonal antibody-based cancer therapy platform. In partnership with Medarex, Inc., the Company has assembled an initial portfolio of four HuRx product candidates, including HuRx-Prostate and the other three are in pre-clinical development.

Jack